Dyadic International (NASDAQ:DYAI) Stock Price Passes Below Fifty Day Moving Average – Here’s What Happened

by · The Cerbat Gem

Dyadic International Inc. (NASDAQ:DYAI – Get Free Report)’s share price passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $0.76 and traded as low as $0.7401. Dyadic International shares last traded at $0.8010, with a volume of 394,340 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a research note on Wednesday. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $3.00.

Check Out Our Latest Analysis on Dyadic International

Dyadic International Stock Up 8.1%

The stock has a market cap of $29.19 million, a PE ratio of -3.48 and a beta of 1.17. The firm has a fifty day moving average of $0.76 and a 200 day moving average of $0.83. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08.

Dyadic International (NASDAQ:DYAI – Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The business had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $0.90 million. Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%. On average, equities research analysts anticipate that Dyadic International Inc. will post 0.13 EPS for the current fiscal year.

Institutional Trading of Dyadic International

Institutional investors and hedge funds have recently bought and sold shares of the business. Marathon Capital Management purchased a new position in Dyadic International during the 3rd quarter worth $41,000. Bank of America Corp DE raised its holdings in Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new stake in Dyadic International in the third quarter valued at about $190,000. Geode Capital Management LLC lifted its position in Dyadic International by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 36,266 shares during the period. Finally, Apis Capital Advisors LLC purchased a new stake in Dyadic International in the 3rd quarter valued at approximately $1,817,000. Hedge funds and other institutional investors own 27.95% of the company’s stock.

About Dyadic International

(Get Free Report)

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.

See Also